AAPP Scientific Poster Session Abstracts
Currently Viewing Abstracts from 2008
2004 | 2005 | 2006 | 2007 | 2008
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026
| Title | Presenter | Type | Session |
|---|---|---|---|
A Double-Blind Placebo-Controlled Trial Comparing Paliperidone ER and Quetiapine in Patients With a Recent Acute Exacerbation of Schizophrenia
|
Encore Presentation | Session 1 | |
|
A Multi-Attribute Decision Making Model for Mood Stabilizer Selection Based on a Survey of Psychiatric Pharmacists.
|
Original Research | Session 1 | |
|
A Noninferiority Comparison of Duloxetine and Venlafaxine XR for the Treatment of Adult Patients with Generalized Anxiety Disorder
|
Encore Presentation | Session 1 | |
|
A PERFORMANCE IMPROVEMENT PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF CHANTIX (VARENICLINE)
|
Work in Progress | Session 1 | |
|
A PRELIMINARY ANALYSIS OF A PHARMACY OUTLIER MANAGEMENT PROGRAM IN A MEDICARE POPULATION
|
Work in Progress | Session 2 | |
|
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GUANFACINE EXTENDED RELEASE IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
|
Encore Presentation | Session 2 | |
|
A Retrospective Evaluation of Adherence with Recommended Monitoring Parameters During Treatment With Valproate and the Impact of Pharmacy Clinical Services
|
Work in Progress | Session 2 | |
|
A RETROSPECTIVE REVIEW OF THE EFFECTS OF DEPRESSION ON WEIGHT LOSS POST-BARIATRIC SURGERY
|
Work in Progress | Session 1 | |
|
A STUDY METHODOLOGY TO OPTIMALLY EVALUATE THE INTRA-PATIENT PHARMACODYNAMIC EFFECT OF SMALL CHANGES IN PLASMA VALPROIC ACID (VPA) CONCENTRATION VIA INTRAVENOUS SODIUM VALPROATE IN EPILEPSY PATIENTS EXHIBITING A PHOTOPAROXYSMAL RESPONSE.
|
Work in Progress | Session 2 | |
|
Acute dystonic reaction with ziprasidone in a 13 year old due to a medication dosing error
|
Encore Presentation | Session 2 | |
|
ADOLESCENT ADHD: ATOMOXETINE MAINTENANCE EFFECTS ON AGE-APPROPRIATE DEVELOPMENTAL/ADAPTIVE FUNCTIONING
|
Encore Presentation | Session 1 | |
|
An Evaluation of the Efficacy and Safety of Duloxetine among Hispanic Americans with Major Depressive Disorder and Pain
|
Original Research | Session 2 | |
|
Antidepressant Use in Bipolar Disorder: A Retrospective Study in a State Inpatient Psychiatric Hospital
|
Original Research | Session 1 | |
|
Antipsychotic Induced Transaminase Elevation: A Case Series
|
Therapeutic Case Management | Session 1 | |
|
Assessment of Depression After an Acute Myocardial Infarction
|
Work in Progress | Session 2 | |
|
Assessment of Ethnicity on a Butyrylcholinesterase Variant in Alzheimer’s Patients and Normal Volunteers
|
Original Research | Session 1 | |
|
Attitudes and Beliefs of Pharmacy Students toward the Mentally Ill
|
Work in Progress | Session 1 | |
|
ATTITUDES OF PHARMACY STUDENTS TOWARD MENTAL ILLNESS ACROSS THE PROFESSIONAL CURRICULUM
|
Work in Progress | Session 1 | |
|
AUTOMATIC THERAPEUTIC SUBSTITUTION (ATS) OF RISPERIDONE AND PALIPERIDONE IN BOTH ADULT AND PEDIATRIC PATIENTS
|
Innovative Practices | Session 2 | |
|
Cardiac-Related Abnormalities on Autopsy in People with Severe Mental Illness Treated with Clozapine
|
Encore Presentation | Session 2 | |
|
CHRONIC LEUKOCYTOSIS ASSOCIATED WITH CLOZAPINE TREATMENT
|
Therapeutic Case Management | Session 1 | |
|
CIPROFLOXACIN-INDUCED PSYCHOSIS: A CASE REPORT
|
Innovative Practices | Session 1 | |
|
Clinical Interventions in a large urban psychiatric hospital
|
Original Research | Session 1 | |
|
Clinical Pharmacist Involvement in Assertive Community Treatment (ACT) for the Chronically Mentally Ill
|
Innovative Practices | Session 1 | |
|
Clinician Adherence to Published Metabolic Monitoring Parameters for Use with Second-Generation Antipsychotics in a Private Inpatient Psychiatric Facility
|
Work in Progress | Session 2 | |
|
Clozapine-Treated Psychiatric Inpatients Post-Smoking Cessation: Effect on Psychiatric Symptomatology
|
Original Research | Session 2 | |
|
Color blindness associated with olanzapine
|
Encore Presentation | Session 2 | |
|
Comparative Safety and Tolerability of Alzheimer's Disease Treatment
|
Encore Presentation | Session 2 | |
|
Comparison of antipsychotic injections utilized within twenty-four hours of mechanical restraints
|
Work in Progress | Session 2 | |
|
Cross-sectional evaluation of single versus combination antipsychotic treatment and clinical outcomes in an inpatient psychiatric facility
|
Encore Presentation | Session 2 | |
|
Determining the Correlation Between Cardiovascular Disease and Depression on an Inpatient Family Medicine Service
|
Original Research | Session 2 | |
|
DEVELOPMENT OF AN EVIDENCE BASED HANDBOOK FOR HEALTHCARE PROVIDERS ON EXPOSURE TO PSYCHOTROPIC MEDICATIONS AND OTHER SUBSTANCES DURING PREGNANCY AND LACTATION
|
Innovative Practices | Session 1 | |
|
DEVELOPMENT OF INTERVENTION S STRATEGIES IN THE USE OF MULTIPLE ANTIPSYCHOTICS TO IMPROVE CLIENT HEALTH OUTCOMES
|
Work in Progress | Session 1 | |
|
Discharge follow-up with a pharmacist study: incorporating pharmacist-provided discharge education and medication reconciliation with an outpatient follow-up service for patients with psychiatric illness discharged to an outpatient day treatment program
|
Work in Progress | Session 1 | |
|
DISPOSITION OF D-SERINE IN HEALTHY ADULTS
|
Original Research | Session 1 | |
|
Duloxetine 60 to 120 mg Once Daily for the Prevention of Relapse in Adults with Generalized Anxiety Disorder: A Double-blind Placebo-controlled Trial
|
Encore Presentation | Session 1 | |
|
Duloxetine Hepatic Effects: 2006 Review
|
Encore Presentation | Session 1 | |
|
DULOXETINE-INDUCED TAKOTSUBO CARDIOMYOPATHY: A CASE REPORT
|
Therapeutic Case Management | Session 1 | |
|
Early Onset of Antipsychotic Action in Schizophrenia: A Clinical Marker Discriminating Active Drug from Placebo
|
Encore Presentation | Session 1 | |
|
Early Symptom Change Prediction of Remission in Depression Treatment
|
Encore Presentation | Session 1 | |
|
Edema and Arthralgia Associated With Olanzapine: A Case Report
|
Therapeutic Case Management | Session 2 | |
|
Effects of adding loxapine to an atypical antipsychotic in patients with schizophrenia or schizoaffective disorder
|
Work in Progress | Session 2 | |
|
Effects of optimal medication therapy management of depression in human immunodeficiency virus (HIV) infected patients on associated virologic and immunologic outcomes.
|
Work in Progress | Session 2 | |
|
Efficacy and Safety of Fixed-Dose Desvenlafaxine Succinate at 50 mg/d and 100 mg/d in Outpatients With Major Depressive Disorder in 2 Placebo-Controlled Trials
|
Encore Presentation | Session 2 | |
|
EFFICACY AND SAFETY OF LISDEXAMFETAMINE DIMESYLATE IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
|
Encore Presentation | Session 2 | |
|
Epinephrine Abuse: A Case Report
|
Therapeutic Case Management | Session 2 | |
|
Ethylglucuronide (EtG) assessed by two methods following fragrance and hand sanitizer exposure in men and women
|
Original Research | Session 1 | |
|
Evalatuion of Monitoring of Atypical Antipsychotic-Related Metabolic Adverse Effects at an Academic VA
|
Work in Progress | Session 2 | |
|
Evaluating Patients Who are Incompetent to Proceed in a Mental Health Facility
|
Work in Progress | Session 2 | |
|
Evaluation of combination antipsychotic treatment in an acute adult psychiatric inpatient unit of a large urban hospital
|
Original Research | Session 1 | |
|
Evaluation of Lacosamide in Diabetic Neuropathic Pain Trials
|
Encore Presentation | Session 1 | |
|
Evaluation of medication adherence among patients discharged from a Veteran’s Affairs residential post traumatic stress disorder treatment program
|
Work in Progress | Session 2 | |
|
Exacerbation of Psychosis: A Case of Possible Varenicline-Mediated Effects in an Intellectually Disabled Adult
|
Therapeutic Case Management | Session 2 | |
|
False-positive phencyclidine immunoassay caused by venlafaxine
|
Encore Presentation | Session 2 | |
|
First exposures in prescription opioid abusers
|
Encore Presentation | Session 1 | |
|
Gabapentin for Severe Behavioral Disturbance Associated with Huntington’s Disease: A Case Report
|
Therapeutic Case Management | Session 2 | |
|
Genetic Association Study of Serum Prolactin Increase in Olanzapine/fluoxetine Combination-treated Patients with Bipolar I Depression
|
Encore Presentation | Session 2 | |
|
Hospitalization and Medication Compliance Associated with the Use of Long-Acting Risperidone Injection for the Treatment of Schizophrenia and Schizoaffective Disorder in a Veteran Population
|
Work in Progress | Session 2 | |
|
Hyperprolactinemia associated with oral ziprasidone
|
Therapeutic Case Management | Session 2 | |
|
Impact of CBC Sampling Time Change on WBC and ANC Values in Clozapine Patients
|
Original Research | Session 2 | |
|
Implementation of metabolic monitoring guidelines in an outpatient psychiatry clinic on patients receiving antipsychotic medications
|
Work in Progress | Session 2 | |
|
IMPROVING MEDICATION MANAGEMENT SUPPORT FOR OLDER ADULTS
|
Work in Progress | Session 1 | |
|
Increasing adverse drug reaction reporting in a 100 bed acute care behavioral health center
|
Work in Progress | Session 1 | |
|
Innovative Practice: The Pharmacist as an Expert Witness: Psychotropic Medication Use and Breastfeeding
|
Innovative Practices | Session 2 | |
|
Interaction Between Apolipoprotein E Genotype and Serum Interleukin-6 Levels in Predicting Cognitive Decline Among Rural Elders
|
Original Research | Session 1 | |
|
Intramuscular ziprasidone usage by emergency medical services
|
Work in Progress | Session 1 | |
|
Lacosamide: Efficacy and Safety as Oral Adjunctive Treatment for Partial-Onset Seizures
|
Encore Presentation | Session 1 | |
|
LISDEXAMFETAMINE DIMESYLATE EFFECT SIZE IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
|
Encore Presentation | Session 1 | |
|
LITHIUM – INDUCED DIABETES INSIPIDUS?
|
Therapeutic Case Management | Session 2 | |
|
Management of trauma-related nightmares in an eating disorder patient
|
Therapeutic Case Management | Session 1 | |
|
Medication Reconciliation at a Psychiatric Hospital
|
Innovative Practices | Session 1 | |
|
Memantine Discontinuation in Nursing Home Residents with Alzheimer’s Disease is Associated with Increased Psychotropic Drug Use and Decreased Weight
|
Encore Presentation | Session 1 | |
|
METABOLIC CONSEQUENCES OF USING LOW-DOSE QUETIAPINE FOR INSOMNIA IN PSYCHIATRIC PATIENTS
|
Work in Progress | Session 1 | |
|
MILNACIPRAN FOR THE TREATMENT OF FIBROMYALGIA SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
|
Encore Presentation | Session 2 | |
|
MILNACIPRAN TREATMENT FOR FIBROMYALGIA SYNDROME: ONE-YEAR DURABILITY OF RESPONSE
|
Encore Presentation | Session 1 | |
|
Minimal lot-to-lot variability in mg tablet content for enteric-coated, delayed-release divalproex sodium and in divalproex sodium extended-release tablets.
|
Original Research | Session 2 | |
|
Minimal variability for in-vitro dissolution profiles for numerous batches of extended-release divalproex sodium tablets, implicating predictability in in-vivo bioavailability.
|
Original Research | Session 2 | |
|
Neuroleptic malignant syndrome after discontinuation of olanzapine: A case report
|
Session 2 | ||
|
Olanzapine Maintenance Treatment for Bipolar I Disorder: Numbers Needed to Treat or Harm
|
Encore Presentation | Session 1 | |
|
ONCE-DAILY ATOMOXETINE FOR ADULT ADHD: A 6-MONTH, DOUBLE-BLIND TRIAL
|
Encore Presentation | Session 1 | |
|
Perceptions of Mood Stabilizing Medications for the Treamtent of Bipolar Disorder: A Survey of Psychiatric Pharmacists
|
Work in Progress | Session 1 | |
|
Pharmacist Interventions to Decrease Use and Increase Documentation of Multiple Antipsychotic Agents at Discharge
|
Innovative Practices | Session 1 | |
|
Phosphodiesterase 11A (PDE11A) Gene is Associated with Lithium Response in Bipolar Disorder
|
Encore Presentation | Session 1 | |
|
Physiological Response to a Speech Stressor Presented in a Virtual Reality Environment
|
Original Research | Session 1 | |
|
PRESMA study: Pilot study assessing the impact of systematic monitoring by a pharmacist on the management of metabolic side effects among patients taking an atypical antipsychotic
|
Original Research | Session 1 | |
|
Promotion of Health and Wellness in Coal Miners Through a Pharmacist-Managed Tobacco Cessation Program
|
Work in Progress | Session 1 | |
|
Psychiatric Antecedents and Subsyndromal Anxiety in Patients with Alcohol Dependence: Effects of Acamprosate
|
Encore Presentation | Session 1 | |
|
Psychiatric Pharmacy in a University Student Health System
|
Innovative Practices | Session 1 | |
|
Psychotropic Medication Adherence: Implications for Post-Release Success
|
Work in Progress | Session 2 | |
|
RANDOMIZED, DOUBLE-BLIND STUDY OF GUANFACINE EXTENDED RELEASE IN CHILDREN AGED 6 TO 17 YEARS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
|
Encore Presentation | Session 2 | |
|
RATES OF ADHERENCE TO ANTIPSYCHOTIC MEDICATIONS IN A POPULATION OF PATIENTS WITH BIPOLAR DISORDER OR SCHIZOPHRENIA IN A COMMUNITY MENTAL HEALTH SETTING – EVALUATION OF 60-DAY REFILL DATA
|
Work in Progress | Session 1 | |
|
Recent Findings of Two National Alliance on Mental Illness (NAMI ) Surveys:
|
Innovative Practices | Session 2 | |
|
Rehospitalization after Discontinuation of Paliperidone ER in Patients with Schizophrenia
|
Original Research | Session 1 | |
|
Rehospitalization Rates Among Patients with Schizophrenia
|
Work in Progress | Session 1 | |
|
Relationship Between Function and Employment Status in Patients With Schizophrenia
|
Original Research | Session 1 | |
|
Relationship between the catechol-o-methyltransferase (COMT) Val158Met polymorphism and antipsychotic response in first episode psychosis
|
Original Research | Session 1 | |
|
Resource Use Patterns Over 24 Months for Patients With Schizophrenia Who Initiated Therapy With Risperidone Long-Acting Injectable
|
Original Research | Session 2 | |
|
Results of initial metabolic clinic screening of 93 patients treated with antipsychotics
|
Original Research | Session 2 | |
|
Retrospective evaluation of a potential interaction between warfarin and trazodone in patients stabilized on warfarin.
|
Work in Progress | Session 1 | |
|
Retrospective Evaluation of Ropinirole Associated Psychotic Symptoms in an Outpatient Population Treated for Restless Leg Syndrome and Parkinson’s Disease
|
Original Research | Session 2 | |
|
SCREENING AND MONITORING FOR EXACERBATIONS OF PSYCHIATRIC ILLNESS AND NEW ONSET PSYCHIATRIC SYMPTOMS IN PATIENTS ENROLLED IN A TOBACCO CESSATION PROGRAM
|
Work in Progress | Session 1 | |
|
Seizure Prophylaxis in a Patient with Toxic Clozapine Levels
|
Therapeutic Case Management | Session 1 | |
|
STUDY OF CONCURRENT USE OF ANTIPSYCHOTICS IN THE CALIFORNIA MEDICAID PROGRAM
|
Encore Presentation | Session 1 | |
|
Temporary Inpatient Smoking Cessation: Clinical Implications for Outpatient Antipsychotic Therapy
|
Work in Progress | Session 1 | |
|
The Co-administration of Clozapine and Fluvoxamine: An Evaluation of Effectiveness and Safety
|
Work in Progress | Session 2 | |
|
The Effect of Tai chi in Reducing Anxiety in an Ambulatory Population
|
Original Research | Session 1 | |
|
THE EFFICACY AND SAFETY OF MILNACIPRAN IN THE TREATMENT OF FIBROMYALGIA SYNDROME
|
Encore Presentation | Session 2 | |
|
The Investigator’s Assesment Questionnaire (IAQ) in Clinical Practice Compared With the Simpson Angus Scale, Abnormal Involuntary Movement Scale and Barnes Akathisia Scale
|
Original Research | Session 2 | |
|
The metabolic impact of mood stabilizers, antidepressants and antipsychotics on bipolar and depressed adolescent males.
|
Original Research | Session 2 | |
|
The Role of the Pharmacist in the Recovery Model for Treating Mental Illness
|
Innovative Practices | Session 2 | |
|
The Use of Memantine in the VA Population
|
Work in Progress | Session 1 | |
|
The Value of specialty care in the Treatment of Major Depression: A Kentucky Medicaid Evaluation
|
Original Research | Session 2 | |
|
Tobacco Smoking Behaviors in Bipolar Disorder and Normal as well as Psychiatric Controls
|
Original Research | Session 1 | |
|
Topiramate for Treatment of Postherpetic Neuralgia
|
Therapeutic Case Management | Session 2 | |
|
Topiramate reduces overall symptom burden and nightmares associated with combat-related post-traumatic stress disorder
|
Original Research | Session 1 | |
|
Total valproic acid concentrations from oral enteric-coated divalproex sodium are predictable within epilepsy patients from day-to-day at the same time of day.
|
Encore Presentation | Session 2 | |
|
Treatment of a clozapine-induced seizure with lamotrigine
|
Therapeutic Case Management | Session 1 | |
|
Treatment of the Alcohol Withdrawal Syndrome with Benzodiazepines in an Inpatient VA Setting
|
Work in Progress | Session 1 | |
|
Use of an online community website to enhance communication on clinical pharmacy rotations
|
Encore Presentation | Session 2 | |
|
Weight Gain and the Investigator’s Assessment Questionnaire (IAQ): Clinician Rated Scoring vs. Actual Changes in Patient Weight
|
Original Research | Session 2 | |
|
XR vs XL vs CR vs ER vs SA vs Chrono: What do these suffixes really mean as it pertains to modified-release AEDs?
|
Encore Presentation | Session 2 |